ロード中...
Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma
BACKGROUND: Researches on programmed cell death (PD-1) as neoadjuvant immunotherapy for resectable non-small cell lung cancer is underway, which brings hope for individuals with the disease. However, a study dedicated to lung squamous cell carcinoma (LUSC) specifically has yet to be conducted. Now,...
保存先:
| 出版年: | J Thorac Dis |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AME Publishing Company
2021
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8024839/ https://ncbi.nlm.nih.gov/pubmed/33841966 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd-21-103 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|